Klacid (Clarithromycin)

Clarithromycin binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis. This inhibition prevents the formation of essential bacterial proteins, resulting in a bacteriostatic effect that halts bacterial growth and, at higher concentrations, can be bactericidal.

The dosage of Klacid is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and local guidelines. Healthcare professionals calculate the appropriate infusion rate and total daily amount for each individual case.

Safety data for clarithromycin during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss risks with the patient and consider alternative therapies when appropriate.

To order Klacid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Klacid (clarithromycin) belongs to the macrolide class and is often compared with azithromycin, another macrolide. Clarithromycin generally has a broader spectrum against certain gram‑positive organisms and a higher intracellular concentration, while azithromycin offers a longer half‑life and once‑daily dosing for oral formulations. Choice depends on infection type, resistance patterns, and patient factors.

Klacid should be stored below 25 °C in its original container, protected from light and moisture. The solution must be kept in a clean, dry environment and inspected for particulate matter before use. Once reconstituted, it should be used within the time frame recommended by the manufacturer and discarded if any discoloration occurs.

Klacid is given as an intravenous infusion by a qualified healthcare professional. The solution is typically diluted in a compatible IV fluid and administered over a prescribed period, often 30 minutes to 1 hour, depending on the dose and patient tolerance. Administration should follow aseptic technique and institutional infusion protocols.

Serious risks include QT interval prolongation leading to potentially life‑threatening arrhythmias, severe liver injury (hepatitis or marked enzyme elevation), hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Patients should be monitored for cardiac symptoms, liver function changes, and any signs of severe allergic response during therapy.

Klacid should be avoided in individuals with known hypersensitivity to clarithromycin or other macrolides, those with a history of prolonged QT interval or ventricular arrhythmias, patients receiving contraindicated drugs such as cisapride, and persons with severe hepatic impairment unless benefits clearly outweigh risks.